- Home
- EDF vs TLSA Comparison
EDF vs TLSA Comparison
Compare EDF & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDF | TLSA |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.0M | 155.3M |
| IPO Year | 2010 | 2017 |
Fundamental Metrics
Financial Performance| Metric | EDF | TLSA |
|---|---|---|
| Price | $5.11 | $0.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 146.3K | ★ 256.6K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.72 | $0.91 |
| 52 Week High | $5.67 | $2.60 |
Technical Indicators
Market Signals| Indicator | EDF | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 34.14 | 33.91 |
| Support Level | $4.81 | N/A |
| Resistance Level | $5.19 | $1.48 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 6.19 | 5.17 |
Price Performance
Historical ComparisonAbout EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.